Merck + Co., Inc.

Proteus Digital Health, Inc.

Intra-cellular Therapies, Inc.

Other

Biogen Ma Inc.

Sunesis Pharmaceuticals, Inc.

Otsuka Pharmaceutical Company, Limited

Horizon Therapeutics, LLC

University of Texas System

Io Therapeutics, Inc.

Brigham Young University

Btg International Limited

Onyx Pharmaceuticals, Inc.

Merck Sharp + Dohme Corp.

Gilead Sciences, Inc.

Andrew S Thompson

Mark Zdeblick

Peng Li

Timothy Robertson

Qiang Zhang

John Charles Tomesch

Wei Yao

James David Beard

Hua Cheng

Lawrence P Wennogle

George M Savage

Amir Haleem

Hooman Hafezi

Ross A Miller

Yashar Behzadi

Lonnie Robarge

Brian T Hopkins

Lawrence W Arne

Patrick R Conlon

Tracy J Jenkins

Timothy Raymond Chan

Edward G Corley

Michael J Humora

Aleksandr Pikelny

Xianglin Shi

Xiongwei Cai

James Alan Kerschen

Xiongzhi Zhang

Andrew Michael Allen

Ichiro Shinkai

Thomas R Verhoeven

Robert Duck

Robert C Leichner

Jay Kickliter

Sean Carey

Marc Nijdam

Eric Gnoske

Blake Leverett

Mike Vidales

Theo Wilson

Marc S Kreidler

Edward J Grabowski

Guy R Humphrey

Steven S Pfeiffer

Steven A Weissman

Louis S Crocker

Joseph Abernathy Lewis, Ii

Joseph C DiNardo

James Hutchison

Fataneh Omidvar

Eberhard Wieland

Falko Diedrich

Birgit Neudecker

Huai-Chueh Chang

Vasilios H Iskos

Maki Uragami

Peter C Wade

Roshantha A Chandraratna

Vidyasagar Pradeep Vuligonda

Ralph P Volante

Nobuyoshi Yasuda

Alexander James Bridges

David J Yang

Gregory Notte

Steven D Young

Woo-Baeg Choi

Sean Dalziel

Paul J Reider

Keshab Sarma

Patrick Beaulieu

Lars V Heumann

James Robert Zeller

Brandon Heath Brown

Anna Chiu

Troy Evan Reynolds

Nolan Griggs

Stephen Paul Lathrop

Erika Karplus

Paul B Savage

Rajendra Parasmal Jain

Robert D Larsen

Todd Thompson

Raman Kumar Bakshi

David J Mathre

Arna Diana Ionescu

Marc Jensen

William Bedford Turner

David O'Reilly

Kit Yee Au-Yeung

Jared Lynn Randall

Gerald S Brenner

Olivier Dapremont

Chris H Senanayake

Alan W Douglas

Joseph D Armstrong, Iii

Gregory Moon

Karen C Thompson

Veeraperumanallu Muralidharan

Lisa DiMichele

Steven A King

The present invention provides methods for the preparation of substituted heterocycle fused gamma-carbolines, such as the compound of Formula 2J, as shown below, intermediates useful in producing them and methods for producing such intermediates and such heterocycle fused gamma-carbolines, and as further defined herein.

Process for preparing 1-(4-fluorophenyl)-4-((6bR, 10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one

Methods, systems and compositions that allow for treating a patient according to a patient customized therapeutic regimen are provided. Embodiments of the invention include obtaining dosage administration information from a patient and using the same to tailor a therapeutic regimen for the patient. Embodiments of the invention further include preparing and forwarding to the patient physical pharmaceutical dosages based on the customized therapeutic regimen.

Patient customized therapeutic regimens

Provided herein are systems and methods for implementing a network consensus for a blockchain network that is characterized by one or more, or all, of the following attributes: (1) implementation of a Proof-of-Coverage scheme; (2) lack of permission for nodes to participate in the network; (3) decentralization, with lack of incentives to centralize; (4) byzantine fault tolerance; (5) based on useful work to the network; (6) high confirmed transaction rate; and (7) censor-resistant transactions.

Systems and methods for implementing permissionless network consensus using blockchain

An apparatus that includes a partial power source including a first material and a second material, the partial power source configured to generate, upon contact with a conducting medium, a potential difference between the first material and the second material to provide power to a control device, and generate, using the first material and the second material, a current flow within the conducting medium, the current flow including information encoded based on a variable conductance between the first material and the second material.

Pharma-informatics system

The present invention provides methods for the preparation of substituted heterocycle fused gamma-carbolines, such as Formula 2J, as shown below, intermediates useful in producing them and methods for producing such intermediates and such heterocycle fused gamma-carbolines, and as further defined herein: 

Hydrochloric acid salt of (6bR,10aS)-3-methyl-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3',4&#x2032;:4,5]pyrrolo[1,2,3-de]quinoxaline

Disclosed herein are systems and methods for facilitating data transmission using a decentralized consensus network. The system comprising: a verified and decentralized consensus network comprising a plurality of node, wherein at least one of the nodes is configured to: (a) determine a target node from the plurality of nodes to be verified; verify the target node by validating a geographic location of the target node or a time of the target node; and (c) receive a token for verifying and validating the target node.

Systems and methods for providing and using a decentralized wireless network

Disclosed herein are systems and methods for providing and using a decentralized network using a blockchain. A provider (and/or miner) may provide network coverage to one or more devices in return for tokens on the blockchain. The blockchain may employ a proof-of-coverage scheme to verify (and even guarantee) that the miners are honestly representing the wireless network coverage they are providing. In some instances, the proof of coverage may require the providers to prove coverage periodically, upon demand, and/or at random intervals.

Systems and methods for providing and using proof of coverage in a decentralized wireless network

The ingestible event marker data framework provides a uniform, comprehensive framework to enable various functions and utilities related to ingestible event marker data (IEM data). The functions and utilities include data and/or information having an aspect of data derived from, collected by, aggregated by, or otherwise associated with, an ingestion event.

Ingestible event marker data framework

The present invention provides methods for the preparation of certain optionally substituted heterocycle fused gamma-carbolines of Formula 2F, as shown below and as further defined herein: 

Preparation of certain substituted 1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines and pharmaceutically acceptable salts thereof

A system for smart device networking includes an endpoint that enables communication with a connected device, a bridge that communicates with the endpoint over a PAN and relays PAN communications to a WAN, and a router that connects to the bridge through the WAN and routes communication to and from the endpoint.

Systems and methods for smart device networking

Provided is a process for preparing 4-phenyl-1-butyric acid, comprising: reacting 4-phenyl-1-butanol with sodium chlorite, a nitroxyl radical catalyst and sodium hypochlorite in an organic solvent and a phosphate buffer; and quenching the reaction with sodium sulfite to produce 4-phenyl-1-butyric. Also provided is 4-phenyl-1-butyric acid prepared by such a process.

Procedure for the preparation of 4-phenyl butyrate and uses thereof

Provided herein are systems and methods for implementing a network consensus for a blockchain network that is characterized by one or more, or all, of the following attributes: (1) implementation of a Proof-of-Coverage scheme; (2) lack of permission for nodes to participate in the network; (3) decentralization, with lack of incentives to centralize; (4)fault tolerance; (5) based on useful work to the network; (6) high confirmed transaction rate; and (7) censor-resistant transactions.

Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

Provided herein are compounds useful for the preparation of compounds that have retinoid-like biological activity. Also provided herein are processes for the preparation of compounds that have retinoid-like biological activity.

Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids

Growing community of inventors

Mountainside, NJ, United States of America

Andrew S Thompson